Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.69	$1.75	$1.41 ▼ $5.01	$9.84M	1.29	63,785 shs	17,463 shs
AWH Aspira Women's Health	$0.08 -12.5%	$0.08	$0.08 ▼ $1.56	$2.44M	2.01	1.62 million shs	4.31 million shs
IBIO iBio	$0.74 +9.3%	$0.75	$0.56 ▼ $6.89	$12.24M	0.6	1.40 million shs	1.39 million shs
SNSE Sensei Biotherapeutics	$8.68 +15.7%	$7.87	$5.00 ▼ $17.40	$10.95M	0.26	31,493 shs	49,571 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	0.00%	-0.59%	+1.81%	-9.14%	-48.00%
AWH Aspira Women's Health	0.00%	0.00%	0.00%	0.00%	-92.74%
IBIO iBio	+9.32%	+24.74%	+1.26%	-7.29%	-59.94%
SNSE Sensei Biotherapeutics	+19.31%	+15.72%	+5.85%	+26.16%	-30.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.5902 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.8	1.3
AWH Aspira Women's Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.192 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.6
SNSE Sensei Biotherapeutics	4.5398 of 5 stars	3.7	3.0	0.0	4.8	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	817.16% Upside
AWH Aspira Women's Health	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	574.58% Upside
SNSE Sensei Biotherapeutics	3.33	Buy	$55.00	533.64% Upside

Current Analyst Ratings Breakdown

Latest AWH, IBIO, SNSE, and APRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/2/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$100.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.57	N/A	N/A	$2.30 per share	0.73
AWH Aspira Women's Health	$9.18M	0.27	N/A	N/A	($0.23) per share	-0.36
IBIO iBio	$375K	32.65	N/A	N/A	$1.41 per share	0.53
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$21.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.32	0.00	N/A	N/A	-1,645.01%	-78.90%	-62.67%	N/A
AWH Aspira Women's Health	-$16.69M	-$0.98	N/A	∞	N/A	-165.07%	N/A	-267.23%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
SNSE Sensei Biotherapeutics	-$30.16M	-$21.31	0.00	N/A	N/A	N/A	-72.13%	-61.35%	N/A

Latest AWH, IBIO, SNSE, and APRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	-$0.53	+$0.24	-$0.53	N/A	$0.12 million
8/5/2025	Q2 2025	SNSE Sensei Biotherapeutics	-$6.20	-$3.91	+$2.29	-$3.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
AWH Aspira Women's Health	$1.04	1,268.29%	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.34	5.90
AWH Aspira Women's Health	N/A	0.75	0.70
IBIO iBio	0.05	1.76	1.76
SNSE Sensei Biotherapeutics	N/A	7.64	7.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
AWH Aspira Women's Health	12.19%
IBIO iBio	7.90%
SNSE Sensei Biotherapeutics	10.50%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
AWH Aspira Women's Health	4.30%
IBIO iBio	0.58%
SNSE Sensei Biotherapeutics	23.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.83 million	5.03 million	No Data
AWH Aspira Women's Health	110	29.76 million	16.92 million	No Data
IBIO iBio	100	16.52 million	9.82 million	N/A
SNSE Sensei Biotherapeutics	40	1.26 million	968,000	Not Optionable

AWH, IBIO, SNSE, and APRE Headlines

Recent News About These Companies

Sensei Biotherapeutics Inc trading resumes

August 15 at 9:00 PM | msn.com

Sensei Biotherapeutics Inc trading halted, volatility trading pause

August 15 at 9:00 PM | msn.com

Q3 EPS Estimate for Sensei Biotherapeutics Lifted by Analyst

August 8, 2025 | americanbankingnews.com

Sensei (SNSE) Q2 Loss Narrows 31%

August 6, 2025 | fool.com

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

These 3 health tech stocks spiked 37% in a day; Time to buy?

August 4, 2025 | finbold.comF

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

July 30, 2025 | globenewswire.com

Sensei Biotherapeutics to execute 1-for-20 reverse stock split

June 13, 2025 | kalkinemedia.comK

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

June 13, 2025 | globenewswire.com

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025 | globenewswire.com

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

April 2, 2025 | globenewswire.com

Sensei Biotherapeutics announces initial results from solnerstotug trial portion

March 29, 2025 | markets.businessinsider.com

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

March 28, 2025 | globenewswire.com

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

March 27, 2025 | globenewswire.com

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

February 6, 2025 | zacks.com

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AWH, IBIO, SNSE, and APRE Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.69 0.00 (0.00%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$1.74 +0.05 (+2.72%)

As of 08/15/2025 07:39 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Aspira Women's Health NASDAQ:AWH

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

iBio NYSE:IBIO

$0.74 +0.06 (+9.32%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.02 (+2.27%)

As of 08/15/2025 07:58 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Sensei Biotherapeutics NASDAQ:SNSE

$8.68 +1.18 (+15.73%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$8.03 -0.65 (-7.49%)

As of 08/15/2025 07:56 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time